A Team Approach to Translational Science
Success doesn’t just come from a winning idea or an exciting new concept. Success comes from having a dedicated team behind that idea, with the enthusiasm and commitment to drive it from concept to clinic. The people behind the peptide…
BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Syndrome
Taipei, Taiwan, May 17th, 2022: BRIM Biotechnology, Inc. (“BRIM”) a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”) the world’s leading, ophthalmic research organization, for the late-stage…
A Peptide Approach to Regenerative Medicine
Are regenerative peptides the answer to current challenges in the development of treatments for unmet needs? In an article published in PharmaTimes Magazine, Frank Lee, CSO, and Maria Chen, VP of Business Development, discuss the potential of pigment epithelium-derived factor…
Overcoming Challenges to Provide Affordable Treatments
Peptides and proteins have a wide range of therapeutic uses. These options come, however, with their own advantages and limitations, which must be identified before selecting the right treatment. In an article published in European Biopharmaceutical Review, Maria Chen, VP…
Haishan Jang, BRIM CEO, reveals the biggest challenges of orphan drug development
In an article published in European Biopharmaceutical Review, Haishan Jang, BRIM Biotechnology CEO, reveals the biggest challenges of orphan drug development and the significant breakthroughs that are helping the Life Science industry’s pursuit of innovation. Read the interview to find…
BRIM Biotechnology’s lead candidate BRM421 for Dry Eye Syndrome shows promising results in Phase II clinical trials
Taipei, Taiwan, June 29th, 2021, BRIM Biotechnology, Inc. (“BRIM”) is pleased to advise that the Type C meeting with the US Food and Drug Administration (FDA) for the further development of lead candidate BRM421 for Dry Eye Syndrome (DES) has taken…
